The Claim
Oral administration of BLS-M22 in aged mdx mice with advanced Duchenne muscular dystrophy has no significant effect on body weight, despite evidence of immune activation and functional improvements.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In aged mdx mice with advanced Duchenne muscular dystrophy, oral BLS-M22 treatment does not change body weight, even though other measures such as immune activity and physical function show improvement.
See the scientific wording
In aged mdx mice with advanced Duchenne muscular dystrophy, oral BLS-M22 treatment does not significantly affect body weight, suggesting it does not induce meaningful muscle mass gain despite immune activation and functional improvements.
A probiotic carrying a modified version of a muscle-growth blocker is swallowed, triggering the immune system to make antibodies that bind and disable the blocker. This allows muscles to work better and repair damage more effectively, but the muscles do not grow larger because the body's ability to build new muscle tissue is blocked by advanced disease.
What the research says
1 studyThe probiotic helped the mice run longer and reduced muscle damage, but their weight and muscle size didn’t change — so it didn’t make their muscles bigger, even though it helped them feel better.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.